Chapter 13

Inhibitors of Angiogenesis Based on Thrombospondin-1

Giulia Taraboletti and Katiuscia Bonezzi


Angiogenesis-driven pathologies, including cancer, are sustained by a preponderance of angiogenic factors over endogenous inhibitors of new-vessel formation. Restoring this balance represents a logical therapeutic strategy to treat these pathologies. Therefore, endogenous inhibitors of angiogenesis, and in particular thrombospondin-1 (TSP-1), are a powerful source of potential antiangiogenic tools. Different therapeutic approaches have been proposed to exploit the antiangiogenic properties of TSP-1, including TSP-1 fragments, synthetic peptides and peptidomimetics, gene therapy strategies and agents that up-regulate TSP-1 expression. This review focuses on the possibility of exploiting TSP-1 for the design of antiangiogenic agents, with particular reference on their use in antineoplastic therapies.

Total Pages: 112-126 (15)

Purchase Chapter  Book Details


.Current and Future Application of Artificial Intelligence in Clinical Medicine.
.Thrombosis in Cancer: .
.Frontiers in Clinical Drug Research - Anti-Cancer Agents.
.Head and Neck Cancer: Hallmarks of The Inflammation Ecosystem.